| Protocol | Month to month | 3 months | 6 months | 12 months | 12-month plan, year total |
|---|---|---|---|---|---|
| Standard injection | $129 | $125 | $119 | $115 | $1,380 |
| Microdose (Nov 8, 2026) | $129 | $125 | $119 | $115 | $1,380 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
NexLife sells compounded tirzepatide three ways. The standard weekly injection is the one most people compare, and it is the only one whose price changed in November.
What do you get with NexLife's standard tirzepatide?
A flat monthly price that covers provider review and medical guidance from NexLife Medical Group, a nutrition plan, a 1:1 coaching call, 24/7 support and free expedited shipping. The plan pages say the price is the same at every dose, with no memberships or contracts. Lab work is not listed as included.
The price fell between our two reads: on October 15, 2026 the standard plans were $169, $159, $149 and $139 a month; as of November 6 they are $129, $125, $119 and $115. The flat dose price matters with tirzepatide, because Zepbound's self-pay price rises as the dose climbs.
Microdose
As of November 8, 2026, NexLife's microdose tirzepatide page lists the same prices as the standard plan: $129 month to month, down to $115 a month on 12 months. On our October 15, 2026 read the microdose tiles were higher ($189 down to $147), so older figures are out of date. Whether a microdose protocol suits you is a question for your prescriber.
Sublingual ODT
The orally dissolving tablet runs $229 month to month and $199 a month on 12 months. FDA-approved tirzepatide, sold as Zepbound and Mounjaro, is given by injection, and the SURMOUNT trials tested weekly injections, not tablets.
How does NexLife compare with Zepbound's self-pay price?
Zepbound costs more per fill at every dose. Lilly's self-pay prices, read October 15, 2026, are $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg to 15 mg when each refill is bought within 45 days; otherwise $499 at 7.5 mg and $699 at 10 mg to 15 mg. A Lilly "month" is 28 days, the savings card allows 11 fills a calendar year, and the savings end December 31, 2026.
| Option | At 2.5 mg | At 10 mg |
|---|---|---|
| Zepbound, refills within 45 days | 11 × $299 = $3,289 | 11 × $449 = $4,939 |
| Zepbound, later refills | 11 × $299 = $3,289 | 11 × $699 = $7,689 |
| NexLife, month to month | 12 × $129 = $1,548 | 12 × $129 = $1,548 |
| NexLife, 12-month plan | 12 × $115 = $1,380 | 12 × $115 = $1,380 |
Three caveats keep this honest. The Zepbound label uses 2.5 mg to start treatment, not as a maintenance dose, so a year at 2.5 mg is arithmetic, not a regimen. Eleven 28-day fills cover 308 days, not a full year. And Lilly's savings end December 31, 2026, so 2027 prices are unknown. Even so, at 10 mg the gap is $4,939 − $1,380 = $3,559 against on-time Zepbound fills, with NexLife covering more days.
If you have Medicare Part D, check the GLP-1 Bridge first. Eligible enrollees pay a $50 copay for the Zepbound KwikPen (not vials), Wegovy or Foundayo from July 1, 2026 to December 31, 2027, per CMS. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, though their Part D plan might cover a GLP-1. More on the brand product is on our Zepbound page.
How does NexLife compare with other tracked tirzepatide programs?
Price check against standing prices in our table. Three comparisons (October 15, 2026 reads, unchanged on November 20):
- Mondae is lower month to month. $126 for one month, $3 below NexLife. Prepaid, it is $124 a month for 3 months and $114 a month for 6 months ($684). Two 6-month prepayments come to 2 × $684 = $1,368, which is $12 below NexLife's 12-month total. Mondae printed no 12-month plan.
- Eden Health is equal. $129 every month with no membership fees, the same as NexLife's month-to-month price. No longer-term discount was printed, so a year is 12 × $129 = $1,548.
- Collective is lower, with a condition. $69 a month plus a $199 yearly membership, about $86 a month all-in. A year comes to 12 × $69 + $199 = $1,027, as long as the membership and price hold.
Across 24 compounded tirzepatide programs with a computable all-in figure, the median lowest monthly figure was $149. NexLife's $115 is the fourth-lowest of the 24; the full sort is in our price ranking.
What do the SURMOUNT trials show, and do they apply?
They describe Zepbound and Mounjaro, not compounded tirzepatide. In SURMOUNT-1, tirzepatide 15 mg produced a 20.9% mean reduction in body weight at 72 weeks (treatment-regimen estimand). In SURMOUNT-5, tirzepatide produced a 20.2% mean reduction against 13.7% for semaglutide at 72 weeks. Both used Lilly's manufactured weekly injections under trial conditions.
No trial we cite tested NexLife's compounded product, its microdose protocol or a sublingual tablet, so these numbers are context for the molecule, not a forecast for you. Our SURMOUNT results page covers the trials in more depth.
The Zepbound label carries a boxed warning about thyroid C-cell tumors and says not to use it if you or your family have had medullary thyroid carcinoma or have MEN 2. Discuss those points with your prescriber whichever product you use.
Who is NexLife tirzepatide a fit for, and who should look elsewhere?
- A fit: you are paying cash, accept a compounded product, and want one published price that does not rise with dose.
- Look elsewhere: you want an FDA-approved medication, your insurance covers Zepbound, you qualify for the Medicare Bridge, or the month-to-month price is your deciding factor (Mondae prints $126).
Before you order from any compounder, run through our compounded tirzepatide safety checklist. NexLife's semaglutide prices and every plan length are in NexLife pricing explained.
Frequently asked questions
Is NexLife's tirzepatide the same as Zepbound?
No. NexLife sells compounded tirzepatide, made by state-licensed 503A pharmacies with the drug in Zepbound but not the same product. It is not FDA-approved, and FDA does not review compounded GLP-1s for safety, effectiveness or quality before sale. Zepbound and Mounjaro are Lilly's approved products, and the SURMOUNT trial results apply to them rather than to any compounded version.
How much does NexLife tirzepatide cost for a year?
As arithmetic on NexLife's prices as of November 6, 2026, the 12-month plan comes to $1,380 at $115 a month, and paying month to month for 12 months comes to $1,548 at $129. The microdose plan, priced the same since November 8, 2026, also comes to $1,380 on a 12-month plan, and the sublingual ODT to $2,388. Lab work, if your prescriber orders it, is not listed as included in these prices.
Does NexLife charge more for 10 mg or 15 mg?
Not on the standard plans. NexLife's plan pages say the price is the same at every dose, so a 12-month plan is $115 a month at a starting dose or a maintenance dose. Lilly's self-pay Zepbound prices, read October 15, 2026, rise from $299 at 2.5 mg to $449 at 7.5 mg to 15 mg with on-time refills, or $699 at 10 mg to 15 mg without them.
Is NexLife microdose tirzepatide cheaper than the standard plan?
Not cheaper, but no longer dearer. As of November 8, 2026, NexLife's microdose tirzepatide page lists $129, $125, $119 and $115 a month, the same as the standard plan; on October 15 the microdose tiles were $189 down to $147. Confirm the price at checkout, and ask your prescriber whether microdosing suits you.
How does NexLife's tirzepatide price compare with other tracked programs?
Price check on first-party reads of November 20, 2026: Mondae charged $126 month to month, $3 under NexLife's $129, and $114 a month on a 6-month plan against NexLife's $115 on 12 months. Eden Health charged $129, the same as NexLife. Collective's $69 plus a $199 yearly membership works out to $85.58 a month all-in, and WellMedr, SnagRx and Embody print sale or prepaid figures with conditions.
Can Medicare pay for tirzepatide instead?
For some people. The Medicare GLP-1 Bridge charges eligible Part D enrollees a $50 copay for the Zepbound KwikPen, not vials, from July 1, 2026 to December 31, 2027, per CMS. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, but their Part D plan might cover a GLP-1. Compounded tirzepatide is not covered by the Bridge.
Sources
- NexLife: Compounded tirzepatide, all plans — prices as of 2026-11-06; inclusions and terms read 2026-10-15
- NexLife: Microdose tirzepatide program — microdose prices read 2026-11-08 (equal to the standard plans); earlier tiles read 2026-10-15
- NexLife: Sublingual tirzepatide ODT — read 2026-10-15; unchanged as of 2026-11-06
- Lilly: LillyDirect Zepbound self-pay terms — prices, 45-day refill rule, 11 fills a year and 2026-12-31 end date read 2026-10-15
- FDA label (DailyMed): Zepbound prescribing information — label revised 08/2026; dosing, boxed warning and contraindications read for this site 2026-11-08
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), N Engl J Med — published July 21, 2022
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5), N Engl J Med — published 2025
- CMS: Medicare GLP-1 Bridge — $50 copay, July 1, 2026 to December 31, 2027; read 2026-10-15
- Mondae: Compounded tirzepatide — first read 2026-10-15
- Eden Health: GLP-1 treatments — $129 every month, no membership fees; read 2026-10-15
- Collective: Holistic weight loss — $69 plus $199 yearly membership; read 2026-10-15
Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.
Check NexLife's plans and state availability → See the price index